Список проголосовавших за комментарий " Teva Pharma target lowered to $38 at Barclays — TEVA's loss, MNTA's gain (33.36 -1.16)Barclays lowers their TEVA tgt to $38 from $46. With last night's U.S. District Court decision ruling in favor of the generics, firm sees an increasing likelihood of <strong>MNTA</strong>/Sandoz launching a generic version of TEVA's Copaxone 40mg in the near term, perhaps as soon as later today, upon FDA approval. MNTA and its commercial partner Sandoz still need FDA approval, although with a district court decision rendered, firm expects timely FDA action. <strong>TEVA will likely seek an injunction to block an at-risk launch, although given the facts of the case and IPR decisions invalidating three of the four patents in the case, firm thinks it's unlikely that will be granted. They don't believe TEVA's additional patents will block generics; Equal Weight.</strong>"